NASDAQ: BiondVax Pharmaceuticals Rings The Nasdaq Stock Market Closing Bell

About this Marketsite Event

BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a pharmaceutical company dedicated to the development of a Universal Flu Vaccine, covering all human strains and providing protection for both seasonal and pandemic flu strains, will visit the Nasdaq MarketSite in Times Square.In honor of the occasion, Dr. Ron Babecoff, Chief Executive Officer rang the Closing Bell.BiondVax Pharmaceuticals, a publicly-traded company (TASE:BNDX) (Nasdaq:BVXV) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company's Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone, a blockbuster drug for the treatment of multiple sclerosis.

Media from the Event

Photos and videos have been posted on BiondVax's website: photos | videos.

Read more on Nasdaq's website: http://www.nasdaq.com/marketsite/marketsite-events-detail.aspx?fn=201507-close07102015.txt#3#ixzz3flXTN6BE

BiondVax to Ring Closing Bell and Close Market Trading on NASDAQ on July 10, 2015

BiondVax launches a new investor relations website providing international investors with comprehensive information about the Company, progress and its strategy

Ness Ziona, Israel – July 2, 2015 – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program. This event will be the culmination of a week of meetings as part of a non-deal roadshow with US-based institutional investors and financial analysts.In addition, BiondVax today announced the launch of its new investor relations website, which can be found at www.biondvax.com.Institutional investors or analysts interested in meeting with BiondVax management in New York or wishing to attend the market closing event should contact the Company’s investor relations team.Ron Babecoff, BiondVax’s President and CEO, commented, “We are very much looking forward to launching our investor relations operations in the US. The closing event at the NASDAQ is an excellent starting point and the culmination of a long and an important process for us, of listing our shares in the United States, and by that making ourselves accessible to the US capital market.”